Results of an extensive retrospective study indicate a strong association between glomerular filtration (eGFR) rate and cardiovascular disease morbidity rate.
Read More »Using Semaglutide and Liraglutide To Protect the Kidney?
A two-for-one deal: both cardiovascular benefits and renal protection.
Read More »DKA Leads to Changes in Children’s Cognitive Function
Just one incident of DKA could potentially damage memory in children with type 1 diabetes.
Read More »Ethnicity Can Affect Risk for Diabetes Complications
A diabetes patient’s risk for chronic kidney disease or cardiovascular disease can be impacted by various factors, including ethnic background.
Read More »Analysis of Sotagliflozin’s Effect on Cardiorenal Factors for Type 1 Patients
Can use of the sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2 dual inhibitor in patients with type 1 diabetes preserve kidney function?
Read More »Dipeptidyl Peptidase-4 Role in Patients with Renal Transplant
Diabetes management can be a major factor in renal transplant aftercare; can DPP-4 therapy help improve outcomes?
Read More »Empagliflozin Effect on Major Adverse Kidney Events
A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.
Read More »The Effect of Dapagliflozin on Renal Disease Progression
There is a potential role in using dapagliflozin in patients with CKD.
Read More »Optimal Treatment In T2D For CV Protection
How triple therapy can lead to optimal cardiovascular and renal protection.
Read More »The Benefits of Exenatide From the EXSCEL Study
The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.
Read More »